Upgrade to SI Premium - Free Trial

Mizuho Securities Reiterates Buy Rating and $152 PT on Jazz Pharmaceuticals (JAZZ) Following 4Q Results; 'Optimistic' on Xryen Trials

March 1, 2017 6:20 AM
Mizuho Securities analyst Irina Koffler reiterates Buy rating and $152 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ), as the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles